Dear Sir/ Maam, Please find attached herewith Unaudited Standalone and Consolidated Financial Results for the quarter/ half year ended September 30, 2025. Kindly take the same on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 4.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gian Life Care reported a sharp deterioration in Q2 FY26 (quarter ended September 30, 2025), with standalone revenue from operations falling to Rs 66.00 lakhs from Rs 194.67 lakhs in the same quarter last year, a drop of about 66%. The company swung to a standalone loss of Rs 46.20 lakhs (EPS of Rs -0.45) versus a profit of Rs 14.19 lakhs a year ago. For the six months ended September 30, 2025, standalone loss stood at Rs 40.75 lakhs and consolidated loss at Rs 45.82 lakhs. The auditor (MSNT & Associates LLP) issued a qualified review, flagging that a reported cash balance of Rs 743.78 lakhs sits alongside unpaid statutory dues of Rs 426.66 lakhs and an unpaid bank loan of Rs 359.78 lakhs classified as a Non-Performing Asset (NPA). The auditor was unable to physically verify the cash or obtain satisfactory evidence for why such a large balance is being held while these obligations remain unsettled.
This is a meaningfully negative filing for shareholders — the business has seen revenue collapse and turned loss-making, while the auditor has raised serious red flags about the legitimacy of the cash balance and the company's unpaid statutory and bank obligations (including an NPA). Expect negative market reaction and heightened governance/going-concern scrutiny.